title: The receptor expression pattern in ductal carcinoma in situ predicts recurrence.
abstract: BACKGROUND
  The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence.
  
  
  METHODS
  Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence.
  
  
  RESULTS
  Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6%. The ER-positive/PR-negative/HER-positive receptor pattern represented 50% (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011).
  
  
  CONCLUSIONS
  Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.
authors.affiliation: Department of Surgery, Division of Breast Surgical Oncology, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 725, Little Rock, AR 72205, USA. juakepple@aol.com
authors.forename: Julie
authors.initials: J
authors.lastname: Kepple
authors.forename: Ronda S
authors.initials: RS
authors.lastname: Henry-Tillman
authors.forename: V Suzanne
authors.initials: VS
authors.lastname: Klimberg
authors.forename: Rakshanda
authors.initials: R
authors.lastname: Layeeque
authors.forename: Eric
authors.initials: E
authors.lastname: Siegel
authors.forename: Kent
authors.initials: K
authors.lastname: Westbrook
authors.forename: Soheila
authors.initials: S
authors.lastname: Korourian
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D002278:Carcinoma in Situ / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D011960:Receptors, Estrogen / Q000096:biosynthesis*; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen